Register for PROVENGE Updates
Register to receive information about PROVENGE
By keeping in contact with PROVENGE, you can continuously learn more about an innovative
approach in the fight against advanced prostate cancer. Register for PROVENGE updates
and ongoing communication from PROVENGE.com.
Register For Updates Now
All fields required unless indicated
PRIVACY NOTE: By registering, you agree to our Privacy
Policy. Your personal and contact information will only be used for the
PROVENGE communications you have opted to receive. You may
unsubscribe at any time.
PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.
In controlled clinical trials, serious adverse events reported in the PROVENGE group included acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. Severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.
The most common adverse events (incidence ≥ 15%) reported in the PROVENGE group were chills, fatigue, fever, back pain, nausea, joint ache, and headache.
Please see the Full Prescribing Information.